Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Non Operating Income (2016 - 2025)

ImmunityBio (IBRX) has disclosed Non Operating Income for 12 consecutive years, with -$1.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Non Operating Income fell 16780.0% to -$1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.2 million, a 14393.33% decrease, with the full-year FY2025 number at -$2.2 million, down 14393.33% from a year prior.
  • Non Operating Income was -$1.7 million for Q4 2025 at ImmunityBio, down from -$187000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $7.5 million in Q4 2021 to a low of -$148.1 million in Q4 2023.
  • A 5-year average of -$15.6 million and a median of -$114000.0 in 2025 define the central range for Non Operating Income.
  • Peak YoY movement for Non Operating Income: soared 2751.72% in 2021, then tumbled 124975.0% in 2023.
  • ImmunityBio's Non Operating Income stood at $7.5 million in 2021, then crashed by 985.4% to -$66.2 million in 2022, then plummeted by 123.75% to -$148.1 million in 2023, then skyrocketed by 100.01% to $10000.0 in 2024, then tumbled by 16780.0% to -$1.7 million in 2025.
  • Per Business Quant, the three most recent readings for IBRX's Non Operating Income are -$1.7 million (Q4 2025), -$187000.0 (Q3 2025), and -$278000.0 (Q2 2025).